WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H414887
CAS#: 247925-28-6 (sodium)
Description: mPEG2000-DSPE is used in COVID 19 mRNA vaccines. It is a PEGylated derivative of 1,2-distearoyl-sn-glycero-3-PE . Formulations containing DSPE-MPEG(2000) have been used to prepare liposomes with long circulation time for the delivery of anticancer and antimalarial agents.. mPEG2000-DSPE has also been widely used as hydrophilic surface modifying agent for a variety types of hydrophobic nanoparticles, including recently reported lipid nanoparticle mRNA vaccines.
Hodoodo Cat#: H414887
Name: mPEG2000-DSPE
CAS#: 247925-28-6 (sodium)
Chemical Formula: (C2H4O)n C43H83NO10P • Na
Exact Mass: 0.00
Molecular Weight: 0.000
Elemental Analysis:
Related CAS #: 247925-28-6 (sodium) 147867-65-0 (free acid)
Synonym: mPEG2000-DSPE; 1,2-Distearoyl-ras-glycero-3-PE-N-Polyethyleneglycol-2000; 1,2-Distearoyl-ras-glycerol-3-Phosphatidylethanolamine-N-Polyethyleneglycol-2000; 1,2-Distearoyl-ras-glycerol-3-Phosphoethanolamine-N-Polyethyleneglycol-2000
IUPAC/Chemical Name: sodium 2,3-bis(stearoyloxy)propyl (2-(((2-methoxyethoxy)carbonyl)amino)ethyl) phosphate
InChi Key: SRLOHQKOADWDBV-UHFFFAOYSA-M
InChi Code: InChI=1S/C45H88NO11P.Na/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-43(47)54-40-42(41-56-58(50,51)55-37-36-46-45(49)53-39-38-52-3)57-44(48)35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-5-2;/h42H,4-41H2,1-3H3,(H,46,49)(H,50,51);/q;+1/p-1
SMILES Code: O=P([O-])(OCC(OC(CCCCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCCCC)=O)OCCNC(OCCOC)=O.[Na+]
Appearance: Solid powder
Purity: >90% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: [Jokerst, J. V.; Lobovkina, T.; Zare, R. N.; Gambhir, S. S. Nanoparticle PEGylation for imaging and therapy Nanomedicine 2011, 6 (4), 715−728]
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 0.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Wang T, Yin X, Lu Y, Shan W, Xiong S. Formulation, antileukemia mechanism, pharmacokinetics, and biodistribution of a novel liposomal emodin. Int J Nanomedicine. 2012;7:2325-37. doi: 10.2147/IJN.S31029. Epub 2012 May 8. PMID: 22661889; PMCID: PMC3357979.
2: Vakili-Ghartavol R, Rezayat SM, Faridi-Majidi R, Sadri K, Jaafari MR. Optimization of Docetaxel Loading Conditions in Liposomes: proposing potential products for metastatic breast carcinoma chemotherapy. Sci Rep. 2020 Mar 27;10(1):5569. doi: 10.1038/s41598-020-62501-1. PMID: 32221371; PMCID: PMC7101339.
3: Abdulla JM, Tan YT, Darwis Y. Rehydrated lyophilized rifampicin-loaded mPEG- DSPE formulations for nebulization. AAPS PharmSciTech. 2010 Jun;11(2):663-71. doi: 10.1208/s12249-010-9428-6. Epub 2010 Apr 20. PMID: 20405256; PMCID: PMC2902321.
4: Xiao P, Zhao J, Huang Y, Jin R, Tang Z, Wang P, Song X, Zhu H, Yang Z, Yu N. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies. Pharm Nanotechnol. 2020;8(5):391-398. doi: 10.2174/2211738508666200813141454. PMID: 32787769.
5: Unnam S, Panduragaiah VM, Sidramappa MA, Muddana Eswara BR. Gemcitabine- loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile. Curr Drug Deliv. 2019;16(2):111-122. doi: 10.2174/1567201815666181024112252. PMID: 30360740.
6: Hong J, Liu Y, Xiao Y, Yang X, Su W, Zhang M, Liao Y, Kuang H, Wang X. High drug payload curcumin nanosuspensions stabilized by mPEG-DSPE and SPC: in vitro and in vivo evaluation. Drug Deliv. 2017 Nov;24(1):109-120. doi: 10.1080/10717544.2016.1233589. PMID: 28155567.
7: Kateh Shamshiri M, Jaafari MR, Badiee A. Preparation of liposomes containing IFN-gamma and their potentials in cancer immunotherapy: In vitro and in vivo studies in a colon cancer mouse model. Life Sci. 2021 Jan 1;264:118605. doi: 10.1016/j.lfs.2020.118605. Epub 2020 Oct 20. PMID: 33096119.
8: Nikpoor AR, Jaafari MR, Zamani P, Teymouri M, Gouklani H, Saburi E, Darban SA, Badiee A, Bahramifar A, Fasihi-Ramandi M, Taheri RA. Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study. Int J Pharm. 2019 Aug 15;567:118492. doi: 10.1016/j.ijpharm.2019.118492. Epub 2019 Jul 2. PMID: 31271815.
9: Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 1999 Oct 22;460(1):129-33. doi: 10.1016/s0014-5793(99)01320-4. PMID: 10571074.
10: Wang Y, Liu FR, Xiang HL, Qing H, Chen C, Mao SJ, Li H. [Preparation of CD123 mono-antibody modified tanshinone ⅡA loaded immunoliposome and its in vitro evaluation]. Zhongguo Zhong Yao Za Zhi. 2017 Jun;42(11):2085-2091. Chinese. doi: 10.19540/j.cnki.cjcmm.20170428.002. PMID: 28822152.